IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness
15 Abril 2024 - 9:30AM
IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical
company developing novel, immune-modulating therapeutic cancer
vaccines based on its T-win® platform, today announced that Marjan
Shamsaei, PharmD, joined the company as SVP, Commercial Development
and Portfolio Lead for IO102-IO103, the company’s lead cancer
vaccine candidate currently in a pivotal Phase 3 trial. Ms.
Shamsaei joins the company’s executive team, reporting to IO
Biotech CEO Mai-Britt Zocca, Ph.D., and is based in the United
States.
“Marjan’s extensive oncology product
commercialization and growth strategy expertise will be invaluable
as we progress into the commercial readiness phase for
IO102-IO103,” said Dr. Zocca. “We’re thrilled to welcome Marjan to
the IO Biotech team as we continue to expand our pipeline with
product candidates in multiple cancer indications where the T-Win
platform may prove highly effective.”
Dr. Shamsaei added, “It is an honor to join IO
Biotech’s team during this exciting growth phase in the company. I
consider myself fortunate to have played a role in bringing novel
and transformative cancer therapeutics to patients throughout my
career. I am thrilled to help address the ongoing need to improve
treatment options for people living with cancer, with our lead
program potentially coming to market as early as 2025.”
Dr. Shamsaei is an accomplished executive with
over 25 years of experience in the pharmaceutical and biotechnology
industry developing commercial and portfolio strategies in multiple
therapeutic areas. Most recently, she served as Vice President,
Head of Commercial at Allogene Therapeutics. Prior to this role,
she served in leadership roles at Five Prime Therapeutics (acquired
by Amgen), Genentech, Jazz Pharmaceuticals and SUGEN/Pharmacia
(acquired by Pfizer). Dr. Shamsaei holds a Doctorate in Pharmacy
from the University of California San Francisco and a Bachelor of
Arts in Chemistry from the University of Colorado.
About IO102-IO103
IO102-IO103 is an investigational off-the-shelf
therapeutic cancer vaccine designed to kill both tumor cells and
immune-suppressive cells in the tumor microenvironment (TME) by
stimulating activation and expansion of T cells against indoleamine
2,3-dioxygenase (IDO) and/or programmed death-ligand 1 (PD-L1)
cells. The company is currently conducting a pivotal Phase 3 trial
(IOB-013/KN-D18; NCT05155254) investigating IO102-IO103 in
combination with pembrolizumab versus pembrolizumab alone in
patients with advanced melanoma, a Phase 2 basket trial
(IOB-022/KN-D38; NCT05077709) investigating IO102-IO103 in
combination with pembrolizumab as first line treatment in patients
with solid tumors, and a Phase 2 basket trial (IOB-032/PN-E40;
NCT05280314) investigating IO102-IO103 in combination with
pembrolizumab as neo-adjuvant/adjuvant treatment of patients with
solid tumors.
The clinical trials are sponsored by IO Biotech
and conducted in collaboration with Merck and Merck is supplying
pembrolizumab. IO Biotech maintains global commercial rights to
IO102-IO103.
KEYTRUDA® is a registered trademark of Merck
Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.,
Rahway, NJ, USA.
About IO Biotech
IO Biotech is a clinical-stage biopharmaceutical
company developing novel, immune-modulating therapeutic cancer
vaccines based on its T-win® platform. The T-win platform is based
on a novel approach to cancer vaccines designed to activate T cells
to target the immunosuppressive cells in the tumor
microenvironment. IO Biotech is advancing its lead cancer vaccine
candidate, IO102-IO103, in clinical trials, and additional pipeline
candidates through preclinical development. Based on positive Phase
1/2 first line metastatic melanoma data, IO102-IO103, in
combination with pembrolizumab, has been granted a breakthrough
therapy designation for the treatment of advanced melanoma by the
US Food and Drug Administration. IO Biotech is headquartered in
Copenhagen, Denmark and has US headquarters in New York, New
York.
For further information, please visit
www.iobiotech.com. Follow us on our social media channels on
LinkedIn and X (@IOBiotech).
Forward-Looking Statement
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. Forward-looking statements, including
regarding the timing of the interim and primary analyses of the
company’s Phase 3 trial, current or future clinical trials, their
progress, enrollment or results, or the company’s financial
position or cash runway, are based on IO Biotech’s current
assumptions and expectations of future events and trends, which
affect or may affect its business, strategy, operations or
financial performance, and actual results and other events may
differ materially from those expressed or implied in such
statements due to numerous risks and uncertainties. Forward-looking
statements are inherently subject to risks and uncertainties, some
of which cannot be predicted or quantified. Because forward-looking
statements are inherently subject to risks and uncertainties, you
should not rely on these forward-looking statements as predictions
of future events. These forward-looking statements speak only as of
the date hereof and should not be unduly relied upon. Except to the
extent required by law, IO Biotech undertakes no obligation to
update these statements, whether as a result of any new
information, future developments or otherwise.
Contact:Maryann Cimino, Director of Investor
Relations IO Biotech, Inc.617-710-7305mci@iobiotech.com
IO Biotech (NASDAQ:IOBT)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
IO Biotech (NASDAQ:IOBT)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024